Ecs Botanics Holdings Ltd · ASX:ECS
Ecs Botanics — Shareholder Meeting (November 2026)
12 slides from Ecs Botanics's shareholder meeting presentation, Nov 18, 2026
Slide 1: 2026 Annual General Meeting
rsonal use only ECS Botanics Holdings Ltd 2026 Annual General Meeting Jeremy King Chairman ASX : ECS Nan-Maree Schoerie 18 NOVEMBER 2026 CEO and Managing Director
Slide 2: Disclaimer
Disclaimer rsonal use only This presentation has been prepared by ECS Botanics recommendation in relation to the purchase or sales of contractors or agents about the accuracy, completeness Holdings Limited (“Company”). shares or other securities in any jurisdiction. or fairness of any information or
Slide 3: FY26 marked a material improvement in financial and operating performance
FY26 marked a material improvement in ECS’s financial and operating performance rsonal use only Revenue Branded B2C $21.4m $3.45m ▲ 10% YoY Q4 sales, ▲ 31% YoY; ~71% of Q4 revenue EBITDA Production +$0.6m 5.3 tonnes PCE production ▲ 43% YoY Improved by $5.8m YoY Outdoor trimmed flower ▲ 12% Operatin
Slide 4: From cash burn to sustained positive operating cash flow
From cash burn to sustained positive operating cash flow rsonal use only FY25 Operating Cash Flow Receipts and Net Operating Cashflow ($'000s) -$5.1m $6,000 $500 $5,000 $0 FY26 Operating Cash Flow $4,000 +$0.5m ($500) $3,000 $5.6m YoY improvement ($1,000) $2,000 Q1 FY27 Operating Cash Flow $1,000 ($
Slide 5: FY27 has started with continued commercial momentum
FY27 has started with continued commercial momentum rsonal use only Quarterly Sales OzSun Flower $5.49m $1.33m ▲ 13.1% QoQ ▲ 44.5% YoY Branded B2C Sales Market Momentum $3.91m ▲ 11.9% QoQ ▲ 23.9% YoY, ~71% of sales vs broader tracked panel ▼ 1.9%1 1: Nostradata pharmacy panel subset; indicative only
Slide 6: The next proof points are commercial
The next proof points are commercial Continue taking market share with Australian-grown products Grow Australian brands Expand selected branded formats rsonal use only Build adoption across OzSun, AVANI & differentiated finished-dose products I N V E S T O R Build recurring revenue across Ge
Slide 7: Existing infrastructure provides capacity for further growth
Existing infrastructure provides capacity for further growth rsonal use only Operational FY26 outdoor FY26 PCE Production cost per cultivation trimmed flower production gram infrastructure 3.1 tonnes 5.3 tonnes Reduced 26 PCEs ▼ 33% PCE Protective cropping ▲ 12% YoY ▲ 43% YoY ▼ 44% Outdoor enclosure
Slide 8: Branded B2C sales up 23.9% YoY as the portfolio broadens
Branded B2C sales up 23.9% YoY as the portfolio broadens rsonal use only I N V E S T O R P R E S E N T A T I O N OzSun AVANI Portfolio expansion Value-led Australian-grown portfolio Differentiated finished-dose products Premium brands and differentiated formats $1.33m +35.7% Q1 flower sales YoY caps
Slide 9: Brands continue to scale as OzSun expands internationally
Expanding Brands continue to scale as OzSun expands internationally Monthly Branded Product Australia Sales (AUD)) rsonal use only $1.6M $1.4M I N V E S T O R $1.2M $1.0M $0.8M $0.6M FY27 JUL-OCT $5.42m P R E S E N T A T I O N $0.4M $0.2M ▲ 21.7% YoY $0.0M June 2024 Oct 2024 Feb 2025 June 2025 Oct 2
Slide 10: International pathways provide the next leg of commercial growth
International pathways provide the next leg of commercial growth rsonal use only I N V E S T O R UK – Curaleaf Germany – established Poland - Koyi New Zealand – market entry finished-dose exports Six ECS-branded P R E S E N T A T I O N Australian-grown flower OzSun launched June First flower r
Slide 11: Differentiated IP and exclusive licences broaden the value proposition
Differentiated IP and exclusive licences broaden the value proposition AVANI Advanced | VESIsorb® Terphogz® rsonal use only Patented delivery technology designed to improve absorption Award-winning Californian genetics brand I N V E S T O R and bioavailability of poorly water-soluble compounds
Slide 12: Thank You
E C S B O T A N I C S H O L D I N G S L T D Thank You rsonal use only 2026 Annual General Meeting Call us today at 1300 833 988 Email us at info@ecs-botanics.com For investor and media enquiries: FY27 focus: Tim Dohrmann Branded growth | International execution | Operating leverage | Disciplined cas
ECS Botanics Holdings — Shareholder Meeting (November 2026) on 6ix